Le Lézard
Classified in: Health, Science and technology
Subjects: CHI, PDT, DEI

The Human Change campaign launched at World Economic Forum in Davos to make children's mental health a global priority


'Human change' is happening now, caused by the over-digitalization of children's lives ?the world must prioritize the alignment of technological progress with the healthy development of children.

DAVOS, Switzerland, Jan. 15, 2024 /PRNewswire/ -- Global advocacy campaign, Human Change, launched today in Davos during the World Economic Forum to raise awareness and instigate a transformation in the way children approach social media and the digitalisation of their lives.

Human Change Logo

The campaign, founded by Margarita Louis-Dreyfus, is uniting people from all walks of life ?academics, paediatricians, advocates, practitioners, teachers and most importantly parents and young people ? in a shared commitment to protect children from the detrimental effects of digitalization.

The Human Change campaign is committed to reshaping the global health narrative and bringing the impact of social media and digital devices on children's well-being to the forefront of the global conversation on health.

In a series of cutting-edge panel discussions, international experts in psychology, medicine, business, government, and more will gather at Human Change House to debate how digitalization and social media are changing our children, and how these children as adults will shape future society. Other discussions will focus on how much ed-tech is too much? Do governments have a responsibility to better regulate tech to protect future generations? And what is the impact of digital addiction on the future workforce?

Preeminent clinicians, leaders in their field, will seek answers to these pressing questions and more.

Davos audiences will hear science-backed arguments from Dr. Mitch Prinstein, Chief Science Officer of the American Psychological Association; Boston Children's Hospital's Dr. Michael Rich, founder of the Digital Wellness Lab and Dr. Stacy Drury, Psychiatrist-in-Chief; as well as Dr. Jim Winston, Psychologist and Trustee of the Winston Family Foundation.

In addition, panels will feature Human Change's Dr. Gaia Bernstein, Co-Director of the Gibbons Institute of Law Science and Technology at Seton Hall University School of Law, discussing how lessons should be drawn from the tobacco and food industries; and Chris McKenna, CEO and Founder of Protect Young Eyes, on urgent government regulation needed to curb technology addiction.

The Human Change campaign is proud to share its platform with Larissa May, Founder and Executive Director of #HalftheStory and Dr. Phil McRae, Executive Staff Officer of Alberta Teacher's Association, who are empowering the next generation's relationship with social media, mental health, and technology ? encouraging different perspectives on emerging technologies.

Human Change's leading commentators are gathered to hash out what can be done together with distinguished WEF members, including Frank McCourt of McCourt Global and Julie Inman Grant, Australian eSafety Commissioner.

The Human Change House will be open daily on the Davos Promenade 49, with panels and receptions.

If you wish to attend any events at Human Change House, please RSVP to [email protected].

https://humanchange.com 

Contact information:
Human Change
[email protected]

Logo - https://mma.prnewswire.com/media/2317595/Human_Change_Logo.jpg


These press releases may also interest you

at 06:00
BioInvent International (STO:BINV)Preliminary data presented at ESMO 2024 demonstrate BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatmentIn a patient with a heavily pretreated leiomyosarcoma, BT-001 was able to...

at 05:18
Mox Capital, a trailblazer in alternative investments with AUM of US$1.4 billion, is announcing its strategic support for a vast array and variety of regional high-potential startups. According to COO Nguyen Dinh Giang, Mox Capital seeks to reinforce...

at 05:00
Updated Phase 1 dose-escalation data from ARROS-1 and ALKOVE-1 clinical trials continue to support potential best-in-class profiles for zidesamtinib and NVL-655 Rapid enrollment in Phase 2 portions of the ARROS-1 and ALKOVE-1 clinical trials;...

at 04:20
Pfizer Inc. today announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and safety of BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for patients with BRAF V600E-mutant...

at 04:06
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, announced the latest clinical data on...

at 04:05
Irdeto, the global leader in digital video platform experiences and security, and Bitmovin, the industry leader in video software solutions, today announced a strategic partnership to deliver enhanced secure video streaming experiences. This...



News published on and distributed by: